Home » Stocks » SWAV

ShockWave Medical, Inc. (SWAV)

Stock Price: $129.98 USD -1.51 (-1.15%)
Updated Jan 22, 2021 4:00 PM EST - Market closed
After-hours: $129.00 -0.98 (-0.75%) Jan 22, 7:27 PM
Market Cap 4.45B
Revenue (ttm) 59.39M
Net Income (ttm) -64.57M
Shares Out 34.08M
EPS (ttm) -2.02
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 22
Last Price $129.98
Previous Close $131.49
Change ($) -1.51
Change (%) -1.15%
Day's Open 130.50
Day's Range 129.05 - 131.49
Day's Volume 230,580
52-Week Range 23.16 - 142.05

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
GlobeNewsWire - 5 days ago

SANTA CLARA, Calif., Jan. 19, 2021 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (Nasdaq: SWAV), a pioneer in the development and commercialization of Intravascular Lithotripsy (IVL) to treat co...

The Motley Fool - 1 week ago

No news is good news for this company.

The Motley Fool - 2 weeks ago

No news was good news for the medical device maker.

InvestorPlace - 1 month ago

With so much hype baked into the market, smart speculators may want to consider these under-the-radar breakout stocks for 2021. The post 7 Under-the-Radar Breakout Stocks for 2021 appeared fir...

Other stocks mentioned: CRLBF, FRCOY, FRPT, PCRFY, PRTS, SE
GlobeNewsWire - 1 month ago

Four New C-Codes for IVL Performed Below the Knee in Hospital Outpatient Setting Four New C-Codes for IVL Performed Below the Knee in Hospital Outpatient Setting

Benzinga - 1 month ago

Smid-cap MedTech company ShockWave Medical Inc (NASDAQ: SWAV) has seen its shares appreciate over 120% year-to-date. The ShockWave Analyst: BofA Securities analyst Bob Hopkins downgraded Shock...

GlobeNewsWire - 2 months ago

SANTA CLARA, Calif., Nov. 18, 2020 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development of Intravascular Lithotripsy (IVL) to treat complex calcified cardio...

Seeking Alpha - 2 months ago

ShockWave has key differentiators that look set to make a remedial breakthrough in peripheral vascular interventions. The CAD III and PAD III IVL studies have shown superior efficacy and safet...

Seeking Alpha - 2 months ago

Shockwave Medical, Inc. (SWAV) CEO Douglas Godshall on Q3 2020 Results - Earnings Call Transcript

Zacks Investment Research - 2 months ago

Shockwave Medical (SWAV) delivered earnings and revenue surprises of 30.91% and 34.87%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the...

Benzinga - 2 months ago

Shares of ShockWave Medical (NASDAQ:SWAV) were flat in after-market trading after the company reported Q3 results. Quarterly Results Earnings per share were up 17.39% year over year to ($0.38)...

GlobeNewsWire - 2 months ago

SANTA CLARA, Calif., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (Nasdaq: SWAV), a pioneer in the development and commercialization of Intravascular Lithotripsy (IVL) to treat co...

GlobeNewsWire - 2 months ago

Disrupt PAD III is Largest Randomized Study of Complex Patients Typically Excluded from Clinical Trials Disrupt PAD III is Largest Randomized Study of Complex Patients Typically Excluded from ...

Zacks Investment Research - 2 months ago

Shockwave Medical (SWAV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

GlobeNewsWire - 3 months ago

SANTA CLARA, Calif., Oct. 22, 2020 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (Nasdaq: SWAV), a pioneer in the development and commercialization of Intravascular Lithotripsy (IVL) to treat co...

GlobeNewsWire - 3 months ago

SANTA CLARA, Calif., Oct. 20, 2020 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development and commercialization of Intravascular Lithotripsy (IVL) to treat se...

The Motley Fool - 3 months ago

You won't see many headlines about these stocks. But they're well positioned to deliver big gains.

Other stocks mentioned: CRLBF, DG
GlobeNewsWire - 3 months ago

Positive Disrupt CAD III Data Submitted to FDA in Premarket Approval Application Positive Disrupt CAD III Data Submitted to FDA in Premarket Approval Application

GlobeNewsWire - 3 months ago

SANTA CLARA, Calif., Oct. 01, 2020 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development and commercialization of Intravascular Lithotripsy (IVL) to treat se...

GlobeNewsWire - 4 months ago

SANTA CLARA, Calif., Aug. 26, 2020 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development of Intravascular Lithotripsy (IVL) to treat complex calcified card...

Seeking Alpha - 5 months ago

ShockWave Medical's (SWAV) CEO Doug Godshall on Q2 2020 Results - Earnings Call Transcript

Benzinga - 5 months ago

Shares of ShockWave Medical (NASDAQ:SWAV) moved higher by 1.5% in after-market trading after the company reported Q2 results.

Zacks Investment Research - 5 months ago

Shockwave Medical (SWAV) delivered earnings and revenue surprises of 15.15% and 6.04%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

GlobeNewsWire - 5 months ago

SANTA CLARA, Calif., Aug. 11, 2020 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (Nasdaq: SWAV), a pioneer in the development and commercialization of Intravascular Lithotripsy (IVL) to treat ...

Zacks Investment Research - 5 months ago

Shockwave Medical (SWAV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

GlobeNewsWire - 5 months ago

SANTA CLARA, Calif., July 30, 2020 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development of Intravascular Lithotripsy (IVL) to treat complex calcified card...

GlobeNewsWire - 6 months ago

SANTA CLARA, Calif., July 21, 2020 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (Nasdaq: SWAV), a pioneer in the development and commercialization of Intravascular Lithotripsy (IVL) to treat ...

GlobeNewsWire - 6 months ago

SANTA CLARA, Calif., July 20, 2020 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development of Intravascular Lithotripsy (IVL) to treat complex calcified card...

The Motley Fool - 6 months ago

The company isn't taking the ruling lying down.

GlobeNewsWire - 6 months ago

SANTA CLARA, Calif., July 08, 2020 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development of Intravascular Lithotripsy (IVL) to treat complex calcified card...

The Motley Fool - 6 months ago

Catalysts are potentially on the way for these leading medical device stocks.

Other stocks mentioned: ABT, ISRG
GlobeNewsWire - 7 months ago

SANTA CLARA, Calif., June 16, 2020 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (“Shockwave”) (Nasdaq: SWAV) today announced the pricing of its public offering of 1,700,000 shares of its comm...

GlobeNewsWire - 7 months ago

SANTA CLARA, Calif., June 16, 2020 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (“Shockwave”) (Nasdaq: SWAV) today announced it has commenced an underwritten public offering of 1,700,000 shar...

GlobeNewsWire - 7 months ago

Centers for Medicare & Medicaid Services Issues New Codes for Peripheral Intravascular Lithotripsy Performed in Hospital Outpatient and Inpatient Settings Centers for Medicare & Medicaid Servi...

Seeking Alpha - 8 months ago

ShockWave Medical, Inc. (SWAV) CEO Doug Godshall on Q1 2020 Results - Earnings Call Transcript

Zacks Investment Research - 8 months ago

Shockwave Medical (SWAV) delivered earnings and revenue surprises of -22.92% and 20.52%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the st...

GlobeNewsWire - 8 months ago

SANTA CLARA, Calif., May 12, 2020 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (Nasdaq: SWAV), a pioneer in the development and commercialization of Intravascular Lithotripsy (IVL) to treat c...

Zacks Investment Research - 8 months ago

Shockwave Medical (SWAV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

GlobeNewsWire - 9 months ago

DISRUPT CAD IV Clinical Study to Support Regulatory Device Approval in Japan DISRUPT CAD IV Clinical Study to Support Regulatory Device Approval in Japan

The Motley Fool - 9 months ago

Optimism that the worst might be over with the COVID-19 outbreak fueled investors' enthusiasm for these healthcare stocks.

Other stocks mentioned: ALGN, BHC
GlobeNewsWire - 9 months ago

Last Patient Enrolled in DISRUPT CAD III, the U.S. FDA IDE Study for IVL in Severely Calcified Coronary Arteries Last Patient Enrolled in DISRUPT CAD III, the U.S. FDA IDE Study for IVL in Sev...

The Motley Fool - 9 months ago

An analyst downgrade sparked a sell-off of the medical device maker.

The Motley Fool - 9 months ago

There's no better time than the present to scoop up shares of these high-growth medical device makers.

Other stocks mentioned: ABT, DXCM
The Motley Fool - 10 months ago

It was another brutal start to the trading week.

Other stocks mentioned: GH, NVCR
The Motley Fool - 10 months ago

We're officially in a bear market.

Other stocks mentioned: ALGN, EXAS
Seeking Alpha - 10 months ago

ShockWave Medical Expects To Reap Benefits Of 2019 Preparation

Seeking Alpha - 11 months ago

ShockWave Medical, Inc. (SWAV) CEO Doug Godshall on Q4 2019 Results - Earnings Call Transcript

The Motley Fool - 1 year ago

Despite doubling over a two-month period, this high-growth stock has given back most of its gains. What should investors think?

The Motley Fool - 1 year ago

These medical device stocks should be poised for a happy new year.

Other stocks mentioned: ABT, ISRG

About SWAV

ShockWave Medical, a medical device company, develops and commercializes intravascular lithotripsy technology to treat calcified plaque in patients with peripheral vascular, coronary vascular, and heart valve diseases. The company offers M5 catheters for treating above-the-knee peripheral artery disease; C2 catheters for treating coronary artery disease; and S4 catheters for treating below-the-knee peripheral artery disease. It serves interventional cardiologists, vascular surgeons, and interventional radiologists through sales representatives ... [Read more...]

Industry
Medical Devices
IPO Date
Mar 7, 2019
CEO
Douglas Godshall
Employees
284
Stock Exchange
NASDAQ
Ticker Symbol
SWAV
Full Company Profile

Financial Performance

In 2019, SWAV's revenue was $42.93 million, an increase of 250.05% compared to the previous year's $12.26 million. Losses were -$51.11 million, 24.3% more than in 2018.

Financial Statements

Analyst Forecasts

According to 6 analysts, the average rating for SWAV stock is "Buy." The 12-month stock price forecast is 112.20, which is a decrease of -13.68% from the latest price.

Price Target
$112.20
(-13.68% downside)
Analyst Consensus: Buy